ALK-Abelló A/S
ALK-B
株式のランク
#2433
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
株価
$36.23
最終同期: 2026-10-16
時価総額
$8.04B
変化（1日）
-1.72%
変化（1年）
12.00%
国
DK
取引 ALK-Abelló A/S (ALK-B)
カテゴリー
Healthcare
の時価総額 ALK-Abelló A/S(ALK-B)
時価総額: $8.04B
October 2026時点で、ALK-Abelló A/S の時価総額は $8.04B です。これは、当社のデータによると、ALK-Abelló A/S が世界で2433rd番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
ALK-Abelló A/S の時価総額の履歴（2009 から 2026 まで）
